Search

Displaying results 741 - 750 of 4575 in total
  1. Drug

    Cephaloglycin

    go.drugbank.com/drugs/DB00689
    Approved

    A cephalorsporin antibiotic that is no longer commonly used.

  2. Drug

    Ceforanide

    go.drugbank.com/drugs/DB00923
    Approved

    Ceforanide is administered parenterally. It has a longer elimination half-life than any currently available cephalosporin. Its activity is very similar to that of cefamandole, another second-generation cephalosporin antibiotic, except th...

  3. Drug

    Dornase alfa

    go.drugbank.com/drugs/DB00003
    ApprovedInvestigational

    Dornase alfa cleaves extracellular DNA to 5´-phosphodinucleotide and 5´-phosphooligonucleotide end products without affecting intracellular DNA. … In individuals with cystic fibrosis, extracellular DNA, which is an extremely viscous anion, is released by degenerating leukocytes that accumulate during inflammatory responses to infections.

  4. Drug

    Tinzaparin

    go.drugbank.com/drugs/DB06822
    ApprovedInvestigational

    Tinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa. … Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa.

  5. Drug

    Enzalutamide

    go.drugbank.com/drugs/DB08899
    ApprovedInvestigational

    Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 20...

  6. Drug

    Bemotrizinol

    go.drugbank.com/drugs/DB11206
    Approved

    Compared to older broad-spectrum chemical agents, bemotrizinol is more more fat soluble (oil soluble in cosmetic oils) to aid in efficacy and broad-spectrum activity [A19212].

  7. Drug

    Xylose

    go.drugbank.com/drugs/DB09419
    ApprovedWithdrawn

    Nevertheless, xylose by itself may not necessarily serve many purposes immediately - but its metabolism results in a variety of substrates that can serve important nutritional and biological purposes. … Reduction of xylose by catalytic hydrogenation produces the common food additive sweetener substitute xylitol [DB11195].

  8. Drug

    Dolutegravir

    go.drugbank.com/drugs/DB08930
    ApprovedInvestigational

    [A31342] Dolutegravir was developed by ViiV Healthcare and FDA-approved on August 12, 2013.

  9. Drug

    Recombinant stabilized RSV A prefusion F antigen

    go.drugbank.com/drugs/DB18713
    ApprovedInvestigational

    [L48066] Abrysvo was first approved by the FDA in May 2023 for use in patients ≥60 years of age, and received subsequent approval in August 2023 for use in pregnant individuals for the protection of

  10. Drug

    Belimumab

    go.drugbank.com/drugs/DB08879
    ApprovedInvestigational

    It is produced by recombinant DNA technology in a murine cell (NS0) expression system. … [A251495, L42705] By binding to BLyS and blocking its interaction with B cell receptors, belimumab inhibits the survival of B cells.